Table 2. Distribution of tumour characteristics by body mass index, and adjusted odds ratios for tumour characteristics in relation to body mass index, by the use of HRT: the Swedish Breast Cancer Study 1993–2003.
|
BMI
|
Adjusted OR
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Tumour characteristics | <25 | 25–30 | >30 | P-value* | 25–30 | 95% CI | >30 | 95% CI |
| All women | ||||||||
| Tumour size (cm) | ||||||||
| ⩽2 | 919 (73) | 702 (71) | 241 (64) | |||||
| >2 | 333 (27) | 287 (29) | 133 (36) | 0.0014 | 1.2 | 1.0, 1.4 | 1.6 | 1.2, 2.0 |
| Lymph node positivity | ||||||||
| No | 854 (70) | 651 (68) | 229 (64) | |||||
| Yes | 370 (30) | 313 (32) | 127 (36) | 0.046 | 1.1 | 0.9, 1.4 | 1.3 | 1.0, 1.7 |
| Grade | ||||||||
| 1 | 129(16) | 104 (15) | 37 (15) | |||||
| 2 | 359 (43) | 272 (40) | 104 (41) | 0.9 | 0.6, 1.2 | 0.9 | 0.6, 1.4 | |
| 3 | 339 (41) | 309 (45) | 110 (44) | 0.29 | 1.1 | 0.8, 1.5 | 1.1 | 0.7, 1.6 |
| Oestrogen receptor | ||||||||
| Positive | 710 (78) | 540 (77) | 229 (81) | |||||
| Negative | 199 (22) | 158 (23) | 53 (19) | 0.44 | 1.1 | 0.9, 1.4 | 0.9 | 0.6, 1.3 |
| Progesterone receptor | ||||||||
| Positive | 570 (64) | 468 (68) | 198 (71) | |||||
| Negative | 316 (36) | 220 (32) | 82 (29) | 0.029 | 0.9 | 0.7, 1.1 | 0.8 | 0.6, 1.0 |
| Never hormone replacement therapy | ||||||||
| Tumour size (cm) | ||||||||
| ⩽2 | 531 (72) | 519 (71) | 186 (64) | |||||
| >2 | 207 (28) | 213 (29) | 103 (36) | 0.033 | 1.1 | 0.9, 1.4 | 1.4 | 1.1, 1.9 |
| Lymph node positivity | ||||||||
| No | 496 (69) | 483 (68) | 179 (66) | |||||
| Yes | 222 (31) | 229 (32) | 93 (34) | 0.33 | 1.1 | 0.9, 1.3 | 1.2 | 0.9, 1.6 |
| Grade | ||||||||
| 1 | 67 (13) | 65 (13) | 31 (16) | |||||
| 2 | 229 (46) | 207 (41) | 83 (43) | 0.90 | 0.8 | 0.6, 1.3 | 0.7 | 0.4, 1.1 |
| 3 | 204 (41) | 232 (46) | 80 (41) | 1.1 | 0.8, 1.7 | 0.8 | 0.5, 1.3 | |
| Oestrogen receptor | ||||||||
| Positive | 421 (79) | 395 (77) | 174 (81) | |||||
| Negative | 113 (21) | 116 (23) | 41 (19) | 0.73 | 1.1 | 0.8, 1.5 | 0.9 | 0.6, 1.3 |
| Progesterone receptor | ||||||||
| Positive | 316 (61) | 345 (69) | 150 (70) | |||||
| Negative | 204 (39) | 158 (31) | 63 (30) | 0.0036 | 0.7 | 0.5, 0.9 | 0.6 | 0.4, 0.9 |
| Ever oestrogen–progestin therapy | ||||||||
| Tumour size (cm) | ||||||||
| ⩽2 | 278 (76) | 110 (73) | 28 (65) | |||||
| >2 | 90 (24) | 41 (27) | 15 (35) | 0.15 | 1.2 | 0.8, 1.9 | 1.9 | 0.9, 3.8 |
| Lymph node positivity | ||||||||
| No | 260 (71) | 97 (66) | 21 (50) | |||||
| Yes | 104 (29) | 51 (35) | 21 (50) | 0.0051 | 1.3 | 0.9, 2.0 | 2.7 | 1.4, 5.2 |
| Grade | ||||||||
| 1 | 54 (23) | 26 (24) | 3 (10) | |||||
| 2 | 92 (40) | 36 (34) | 10 (34) | 0.7 | 0.4, 1.4 | 2.0 | 0.5, 7.7 | |
| 3 | 86 (37) | 45 (42) | 16 (55) | 0.084 | 1.3 | 0.7, 2.4 | 3.4 | 0.9, 12.7 |
| Oestrogen receptor | ||||||||
| Positive | 207 (78) | 86 (79) | 28 (78) | |||||
| Negative | 60 (22) | 23 (21) | 8 (22) | 0.86 | 1.1 | 0.6, 1.9 | 1.2 | 0.5, 3.0 |
| Progesterone receptor | ||||||||
| Positive | 187 (71) | 73 (68) | 24 (67) | |||||
| Negative | 75 (29) | 34 (32) | 12 (33) | 0.45 | 1.3 | 0.8, 2.2 | 1.7 | 0.8, 3.7 |
BMI=body mass index (kg m−2); CI=confidence interval; HRT=hormone replacement therapy; OR=odds ratio.
*P-value: Two-sided Mantel–Haenszel χ2 for the distribution between groups.OR adjusted for age at diagnosis (5-year categories), parity (0, 1, 2, 3, and >3), current smoking (yes/no), and age at menopause (<45, 45–49, 50–54, and ⩾55 years).